Here’s a question I’ve never stopped wondering about: why will someone spend an entire evening comparison-shopping to save a few dollars, yet make a multi-million-dollar medical decision after reading a single ad? This isn’t about intelligence. It’s human nature: the more is at stake, the more easily hope takes over, and the more likely we are to skip the most basic step of checking the facts.

The Chinese science writer Wan Weigang has made a similar observation in his newsletter Elite Daily Course: the time we spend on a decision is often mismatched with how much the decision actually matters. We agonize over small purchases and go with our gut on the big ones. This article is about correcting that mismatch.

TL;DR — The persuasive power of these ads depends entirely on you not checking. Japan’s Ministry of Health, Labour and Welfare maintains a public registry of regenerative medicine provision plans, each specifying its approved indications. Matching those against what the ad claims takes about three minutes, and what it might prevent is a seven-figure expenditure.

The previous article covered the regulatory structure: Japan’s regenerative medicine provision plans operate under a notification-and-filing system, not an approval process, and each plan is tied to specific diseases. This article turns that structure into concrete steps.

One number sets the context. In 2016, the Kyoto University Center for iPS Cell Research and Application surveyed the websites of Japanese clinics offering regenerative medicine as private-pay treatment and found that approximately 51.9% contained exaggerated advertising, routinely overstating efficacy while barely disclosing risk. The National Cancer Center conducted a similar survey in 2023, examining the websites of 254 Class 2 regenerative medicine institutions. Over half. That means if you click on one of these ads at random, the odds of encountering a problem are close to a coin toss. That’s exactly why those three minutes are worth spending.

How to Check: One Core Action

The entire verification process comes down to a single move: place the diseases the ad claims to treat side by side with the target diseases listed in the official plan.

Step 1: Find the institution’s official registered name

Ad landing pages rarely display the clinic’s full legal name prominently. Look in the footer or under “Company Information” and note both the legal entity type (medical corporation, general incorporated association, etc.) and any branch names. Different branches of the same brand may belong to separate legal entities with separately filed plans.

Step 2: Search the Ministry of Health, Labour and Welfare public registry

The URL is saiseiiryo.mhlw.go.jp. The “Notified Regenerative Medicine Provision Plans” are organized across three pages by risk level:

  • Class 1: High risk — iPS cells, ES cells, gene therapy
  • Class 2: Medium risk — somatic cells including mesenchymal stem cells
  • Class 3: Low risk — NK cell immunotherapy and similar

Autologous or umbilical cord-derived mesenchymal stem cells, the most common type in consumer advertising, fall under Class 2. Search all three pages using the institution name.

Step 3: Download the description document and find the target diseases

The registry page itself only shows institution name, address, supervising physician, treatment name, and reviewing committee. To see the indications, you must open the description document.

Inside, there is a section that explicitly states the target diseases for that plan, usually along with enrollment criteria such as age range and whether standard treatment has already failed. That section is what you are looking for.

Step 4: Compare the two lists

Write down the diseases the ad claims to treat, then set them beside the target diseases in the plan.

Two points of confusion come up often:

Different cell types are registered under different plans. A clinic may have three separate registrations — mesenchymal stem cells, NK cells, fibroblasts — each tied to different diseases. If an ad promotes mesenchymal stem cell therapy, the “aging-related conditions” listed under the clinic’s NK cell plan cannot be cited as supporting evidence. The cells, mechanisms, and plans are distinct.

Technical names may vary slightly between filings. The same institution may have multiple entries with similar names, filed in different batches or reviewed by different committees. Check every entry, not just the first result.

Six Phrases That Should Make You Stop

Beyond the indication check, these are warning signs at the level of the ad copy itself. None of them is necessarily illegal on its own, but each one warrants a follow-up question.

One: Describing a “notification” as a “certification.” Displaying a photograph of a government filing document is not itself problematic — the document is real. The question is whether the page layout leads readers to conclude that the therapy has been reviewed and approved by the government. If it does, a filing-and-archival document is being presented in the place of an approval. The Ministry of Health, Labour and Welfare’s regulatory case commentary addresses this pattern explicitly.

Two: International organization logos placed beside government documents. FDA, NIH, the International Society for Stem Cell Research, PubMed — if these logos appear alongside a notification document under a headline like “continuously supported by international research,” readers may reasonably infer that this specific therapy has received dual official endorsement from both Japanese and American authorities. The FDA has not granted individual approvals for these types of autologous cell therapies.

Three: A disease list that is implausibly long. The next article will explain the mechanistic reasons. A rough working heuristic: if a single list covers neurodegeneration, cardiovascular disease, metabolic disorders, infection, post-cancer recovery, and cosmetic concerns simultaneously, it has exceeded what any single therapy can plausibly address.

Four: Fear-based before-and-after timelines. “People who act now” versus “people who wait,” paired with diverging curves, implying that inaction accelerates decline. This type of design uses time pressure to drive decisions while providing very little actual information.

Also check where the disclaimers are. If “results vary by individual” is buried near the bottom in small type, placed far from the charts making the claims, most readers will never connect the two.

Five: No section on risks or side effects. A medical decision costing several million yen deserves a clear explanation of possible complications, a statement that this is private-pay treatment outside covered insurance, and some comparison with alternative options. The Ministry of Health, Labour and Welfare requires that advertisements for unapproved or off-label private-pay treatments disclose costs, risks, and other treatment options. The absence of this section is itself a signal.

Six: The ad page is entirely cut off from the clinic’s main website. This one is easy to overlook, but it is revealing. If you cannot find this particular treatment anywhere on the clinic’s main website through normal browsing — the main menu, the pricing page, the FAQ — and the only way in is through a paid ad landing page, that means the clinic has not included this treatment in what it presents to the general public.

Relatedly, if the supervising physician named on the government notification document does not appear in the clinic’s team introductions, that is worth asking about.

What to Check in Taiwan, and Where to Report

Taiwan’s regulatory design is different. Under the Regulations Governing the Broadcasting of Regenerative Medicine Advertisements and Recruitment Advertisements, regenerative medicine ads are subject to prior review: approval before broadcast, with content preserved on record.

In principle, any regenerative medicine ad running in Taiwan has already been reviewed.

The Ministry of Health and Welfare also maintains a Regenerative Medicine Technology Information Hub, which publicly discloses all nationally approved regenerative medicine technology implementation plans, publishes regular annual reports, and provides a complaints channel.

One distinction matters here: a medical technology permit and a pharmaceutical marketing authorization are two separate things. Cell therapy opened under Taiwan’s 2018 Special Regulations operates as a “medical technology” authorization. A drug marketing license, governed by the Regenerative Medicine Medicinal Products Act (in force from January 2026), follows an entirely different approval track with different evidentiary requirements.

If an ad conflates these two, treat it as a flag.

For cross-border advertising disputes, Taiwanese consumers can file complaints with the Ministry of Health and Welfare or the Executive Yuan’s Consumer Protection Commission. On the Japanese side, the relevant channels are the Ministry of Health, Labour and Welfare’s medical advertising regulation office and the Consumer Affairs Agency.

Why These Three Minutes Are Worth It

I recognize the ask. Telling someone who is searching for treatment options for a sick family member to “check the database first” can sound out of touch. The people who click on these ads are often those who have already gone through standard treatment and are still looking for a way forward. In that situation, hope can easily outpace judgment.

That is precisely why these three minutes matter. You are comparing two lists: what the ad says the therapy treats, and what the government document says it treats. No medical background required. And what it might prevent is a seven-figure expenditure and an unnecessary trip abroad.

The next article goes one layer deeper. Even when the indications match, there is a prior question: after mesenchymal stem cells are administered intravenously, where do the cells actually go, how long do they survive, and what do they do? That article will explain why the sheer length of a disease list is itself a diagnostic criterion.

References

Public Databases Used for Verification

Surveys on Exaggerated Advertising

FDA Consumer Alert (Source for the Non-Approval List)

Japanese Advertising Regulations (Legal Basis for the Red Flags)

Taiwan

  • Regulations Governing the Broadcasting of Regenerative Medicine Advertisements and Recruitment Advertisements; Regenerative Medicine Act; Regenerative Medicine Medicinal Products Act: full text available via the Laws and Regulations Database of the Republic of China (law.moj.gov.tw).
  • Ministry of Health and Welfare, Regenerative Medicine Technology Information Hub (public disclosure of approved plans, annual reports, complaints channel).
  • Cross-border advertising complaints: Ministry of Health and Welfare; Executive Yuan Consumer Protection Commission; for matters in Japan, the Ministry of Health, Labour and Welfare medical advertising regulation office and the Consumer Affairs Agency.

Series: Notification Is Not Approval · After MSCs Enter the Bloodstream, Where Do the Cells Actually Go? · The Logic Behind the Dual-Track System